Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27008627 | 1.00 | EPHX2 (0.44) | EPHX2L3MBTL1FAAHHTTRAB9A | |
| SCHEMBL24433527 | 0.81 | MGLL (0.44) | FAAH | |
| SCHEMBL29779821 | 0.81 | MGLL (0.44) | FAAH | |
| SCHEMBL29657027 | 0.81 | MGLL (0.44) | FAAH | |
| SCHEMBL29656914 | 0.81 | MGLL (0.44) | FAAH | |
| SCHEMBL27008496 | 0.79 | SMN1; SMN2 (0.43) | HTTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL27008487 | 0.79 | HCRTR2 (0.50) | EPHX2HTTRAB9AALDH1A1NPC1 | |
| SCHEMBL27008607 | 0.79 | SMN1; SMN2 (0.43) | HTTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL27008613 | 0.79 | HCRTR2 (0.50) | EPHX2HTTRAB9AALDH1A1NPC1 | |
| SCHEMBL27008591 | 0.79 | KCNH2 (0.39) | ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | EPHX2 1473/4885L3MBTL1 488/4885FAAH 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.